Helicobacter pylori blood biomarker for gastric cancer risk in East Asia
东亚胃癌风险的幽门螺杆菌血液生物标志物
基本信息
- 批准号:9091479
- 负责人:
- 金额:$ 44.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-01 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:AgeAntibioticsAntibodiesAsiansAtrophic GastritisBiological MarkersBloodBlood specimenChinaChinese PeopleCohort StudiesDevelopmentDiagnosisDiagnosticDiseaseDistalEnrollmentEtiologyFar EastGenetic VariationGrantHealthHelicobacter pyloriIncidenceIndividualInfectionInflammationIntegration Host FactorsJapanKoreaLeadLesionMalignant NeoplasmsMeasuresModelingMorbidity - disease rateNested Case-Control StudyPTGS2 genePathway interactionsPepsinogen APilot ProjectsPopulationPredictive ValuePredispositionPremalignantPreventionPrevention strategyProteinsRiskRisk FactorsRisk MarkerRoleScreening for Gastric CancerSerologic testsVirulence Factorsbiomarker panelcancer riskcohortcost effectivedisorder preventiongastric cancer preventionhigh riskimprovedmale healthmalignant stomach neoplasmmenmolecular markermortalitynew technologynovelnovel markerpredictive modelingprospectiveresponsesextoolurinary
项目摘要
DESCRIPTION (provided by applicant): Gastric cancer is the second most deadly cancer in the world, and incidence and mortality rates are highest in East Asia. Infection with Helicobacter pylori, the strongest known risk factor for gastric cancer, is also endemic throughout East Asia, but only a small percentage of infected individuals ever develop gastric cancer. Due to the high level of genetic variation among H. pylori isolates, it may be possible to identify risk markers tht could classify H. pylori-infected individuals into high- and low-risk groups, presenting a unique opportunity for cost- effective disease prevention. This is especially significant because H. pylor eradication has been found to effectively reduce gastric cancer incidence. Currently, however, there is no known biomarker that is feasibly assessed that can estimate a substantially significant increase in risk for gastric cancer. Recently, we performed a pilot study nested in a prospective Chinese cohort to identify potential H. pylori blood biomarkers. Utilizing novel H. pylori multiplex serology, we found that increasing number of sero-positive results to six H. pylori proteins (Omp, HP0305, HyuA, HpaA, CagA, and VacA) may be a novel biomarker panel for gastric cancer risk. We have found that this biomarker panel is significantly stronger at discriminating risk than evidence of the CagA protein alone, resulting in those individuals with antibodies to all six indicated H. pylori proteins having a three- to five-fold increase in risk of
distal gastric cancer. Replication of these results in other populations, particularly other high-rsk East Asian populations who may be colonized by similar Asian strains, would enhance the possibility of utilizing these H. pylori blood biomarkers for gastric cancer screening. Thus, we have assembled a consortium of eight prospective cohort studies in the high gastric cancer-incidence populations of China, Japan, and Korea, to determine if we can replicate this novel biomarker panel for gastric cancer risk. We aim to: assess the association of H. pylori protein antibody levels in pre-diagnostic blood samples with gastric cancer risk in 2,000 distal gastric cancer cases and 2,000 controls in East Asia; determine if host factors of inflammation or susceptibility to inflammation aid in assessing gastric cancer risk; and build a predictive model for gastric cancer risk in East Asia that includes H. pylori blood biomarkers and enables us to categorize individuals into high and low-risk groups for gastric cancer, and then validate this model among individuals with both cancer and precancerous lesions in a high-risk population. This project is proposed in direct response to PA-11-158: Biomarkers of Infection-Associated Cancers (R01), for which applicants were invited to investigate the association of H. pylori and gastric cancer "to identify subpopulations of exposed individuals who are likely to develop cancer." Should we ascertain and validate a risk prediction model that predicts increased risk in high-incidence populations, we will create the opportunity to substantially increase prevention of this deadly cancer through targeted prevention strategies among H. pylori-infected individuals at highest risk, while also reducing unnecessary antibiotic use among those at low risk.
描述(由申请人提供):胃癌是世界上第二大致命癌症,发病率和死亡率在东亚地区最高。幽门螺杆菌感染是已知的最强的胃癌危险因素,在整个东亚地区也很流行,但只有一小部分感染者会患上胃癌。由于幽门螺杆菌分离株之间存在高水平的遗传变异,因此有可能识别出风险标记,将幽门螺杆菌感染的个体分为高风险组和低风险组,从而为具有成本效益的疾病预防提供了独特的机会。这尤其重要,因为根除幽门螺杆菌已被发现可以有效降低胃癌的发病率。然而,目前还没有经过可行评估的已知生物标志物可以估计胃癌风险的显着增加。最近,我们在中国前瞻性队列中进行了一项试点研究,以确定潜在的幽门螺杆菌血液生物标志物。利用新型幽门螺杆菌多重血清学,我们发现六种幽门螺杆菌蛋白(Omp、HP0305、HyuA、HpaA、CagA 和 VacA)血清阳性结果数量的增加可能是胃癌风险的新型生物标志物组。我们发现,该生物标志物组在区分风险方面比单独使用 CagA 蛋白的证据明显更强,导致那些对所有六种指定幽门螺杆菌蛋白均具有抗体的个体,其患幽门螺杆菌感染的风险增加了三到五倍。
远端胃癌。在其他人群中复制这些结果,特别是可能被类似亚洲菌株定植的其他高风险东亚人群,将增强利用这些幽门螺杆菌血液生物标志物进行胃癌筛查的可能性。因此,我们在中国、日本和韩国的胃癌高发人群中组建了八项前瞻性队列研究,以确定我们是否可以复制这种新型胃癌风险生物标志物组。我们的目标是:评估东亚地区 2,000 名远端胃癌病例和 2,000 名对照者的诊断前血液样本中幽门螺杆菌蛋白抗体水平与胃癌风险的关联;确定炎症或炎症易感性的宿主因素是否有助于评估胃癌风险;建立东亚地区胃癌风险的预测模型,其中包括幽门螺杆菌血液生物标志物,使我们能够将个体分为胃癌高风险组和低风险组,然后在高风险人群中同时患有癌症和癌前病变的个体中验证该模型。该项目的提出是为了直接响应 PA-11-158:感染相关癌症的生物标志物 (R01),该项目邀请申请人调查幽门螺杆菌与胃癌的关联,“以确定可能患癌症的暴露个体的亚群”。如果我们确定并验证一个预测高发病人群风险增加的风险预测模型,我们将创造机会,通过对高风险幽门螺杆菌感染者采取有针对性的预防策略,大幅加强对这种致命癌症的预防,同时减少低风险人群不必要的抗生素使用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MEIRA EPPLEIN其他文献
MEIRA EPPLEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MEIRA EPPLEIN', 18)}}的其他基金
Delineating the underlying reasons for the racial disparity in gastric cancer incidence in the United States
描绘美国胃癌发病率种族差异的根本原因
- 批准号:
10518553 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别:
Delineating the underlying reasons for the racial disparity in gastric cancer incidence in the United States
描绘美国胃癌发病率种族差异的根本原因
- 批准号:
10685530 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别:
Project 2: Racial differences in host immune response and gastric carcinogenesis: Translating underlying biology to promote gastric cancer interception
项目2:宿主免疫反应和胃癌发生的种族差异:转化基础生物学以促进胃癌拦截
- 批准号:
10037509 - 财政年份:2020
- 资助金额:
$ 44.36万 - 项目类别:
Project 2: Racial differences in host immune response and gastric carcinogenesis: Translating underlying biology to promote gastric cancer interception
项目2:宿主免疫反应和胃癌发生的种族差异:转化基础生物学以促进胃癌拦截
- 批准号:
10263344 - 财政年份:2020
- 资助金额:
$ 44.36万 - 项目类别:
Helicobacter pylori protein-specific antibodies and colorectal cancer risk
幽门螺杆菌蛋白特异性抗体与结直肠癌风险
- 批准号:
8894172 - 财政年份:2015
- 资助金额:
$ 44.36万 - 项目类别:
Helicobacter pylori blood biomarker for gastric cancer risk in East Asia
东亚胃癌风险的幽门螺杆菌血液生物标志物
- 批准号:
8593567 - 财政年份:2013
- 资助金额:
$ 44.36万 - 项目类别:
Helicobacter pylori blood biomarker for gastric cancer risk in East Asia
东亚胃癌风险的幽门螺杆菌血液生物标志物
- 批准号:
8699730 - 财政年份:2013
- 资助金额:
$ 44.36万 - 项目类别:
Helicobacter pylori blood biomarker for gastric cancer risk in East Asia
东亚胃癌风险的幽门螺杆菌血液生物标志物
- 批准号:
9464051 - 财政年份:2013
- 资助金额:
$ 44.36万 - 项目类别:
Helicobacter pylori subtypes, inflammation, and gastric cancer risk
幽门螺杆菌亚型、炎症和胃癌风险
- 批准号:
8677779 - 财政年份:2011
- 资助金额:
$ 44.36万 - 项目类别:
Helicobacter pylori subtypes, inflammation, and gastric cancer risk
幽门螺杆菌亚型、炎症和胃癌风险
- 批准号:
8481198 - 财政年份:2011
- 资助金额:
$ 44.36万 - 项目类别:
相似海外基金
Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
- 批准号:
2902098 - 财政年份:2024
- 资助金额:
$ 44.36万 - 项目类别:
Studentship
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
- 批准号:
EP/Z533026/1 - 财政年份:2024
- 资助金额:
$ 44.36万 - 项目类别:
Research Grant
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
- 批准号:
BB/Y004035/1 - 财政年份:2024
- 资助金额:
$ 44.36万 - 项目类别:
Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
- 批准号:
FT230100468 - 财政年份:2024
- 资助金额:
$ 44.36万 - 项目类别:
ARC Future Fellowships
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 44.36万 - 项目类别:
Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 44.36万 - 项目类别:
Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
- 批准号:
MR/Y033809/1 - 财政年份:2024
- 资助金额:
$ 44.36万 - 项目类别:
Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
- 批准号:
494853 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
- 批准号:
2884862 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
- 批准号:
2904356 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Studentship